Treating hematologic malignancies with engineered T cells

This article explores new targets in solid tumors for treating patients with hematologic malignancies.

Related Keywords

United States ,Netherlands ,New Jersey ,Maria Osipova ,Michel Sadelain ,John Haanen ,Stanford Center ,International Journal Of Molecular Sciences ,Oncology Department ,Netherlands Cancer Institute ,Memorial Sloan Kettering Cancer Center ,Sponsored Content ,Medical Oncology Department ,Netherlands Cancer ,Chimeric Co Stimulatory Receptor ,Memorial Sloan Kettering Cancer ,Cancer Cell ,Signal Neutralization ,Inhibitable Protease ,Molecular Sciences ,Content Policy ,News Medical Net ,T Cells ,Hematologic Malignancies ,War Cell ,